The diagnostic power to differentiate CCA from normal subjects and the best-performing model was a combination of at least four biomarkers, namely, S100A9, MUC5AC, angiopoietin-2, and CA19-9 with a sensitivity of 90%, specificity of 95% and an AUC of 0.975. This evidence concerns the gene S100A9 and cholangiocarcinoma.